CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 enrolled
Drug / intervention
BIA 9-1067 +1 moredrug
Likely dose
BIA 9-1067 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01532141
NCT01532141Phase 1Completed
CompareCT.gov

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy Subjects

Bial - Portela C S.A.·interventional·Posted Feb 14, 2012·Updated Aug 20, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 9-1067 and Rasagiline for Parkinson Disease. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the effect of rasagiline on BIA 9-1067 pharmacokinetics in healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesFrance
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 14, 2012
Enrollment StartNov 1, 2009
Primary CompletionFeb 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.4 years ago

Interventions

BIA 9-1067drug

50 mg BIA 9-1067 (single-dose)

Rasagilinedrug

1 mg rasagiline (single-dose)